Breaks Categories: Stock Spotlights

TuesdayApr 23, 2024 3:52 pm

CBDNewsBreaks – Golden Triangle Ventures Inc. (GTVH) Making Significant Strides to Create Premier Entertainment Destination

Golden Triangle Ventures (OTC: GTVH) and its entertainment division, Lavish Entertainment, have made significant progress in transforming into reality the vision for a premier destination for year-round, world-class music, entertainment and art. “Since the announcement of Destino Ranch, a planned 638-acre property conveniently located within a short drive from large population centers such as Phoenix, Los Angeles and Las Vegas, Lavish Entertainment has officially activated the first phase of development. This phase includes the execution of a land-use-and-development agreement outlining exclusive rights to use and operate on the property. Phase one development will focus on the first nearly-70 acres of…

Continue Reading

WednesdayApr 10, 2024 3:30 pm

CBDNewsBreaks – Software Effective Solutions Corp. (SFWJ) Moving Toward Vision to Become World-Leading Integrated Cannabis Company

Software Effective Solutions (OTC: SFWJ), a leading holding company in the cannabis industry, is growing its footprint through savvy acquisitions. “[In February], the company announced that it was in the final stages of negotiations to acquire its sixth cannabis company in Colombia. This strategic acquisition is extremely significant because the targeted company holds a unique cannabis genetics license, which MedCana believes will revolutionize its potential to create and register unique cannabis genetic varieties for production and commercialization… Early in March, MedCana completed the previously announced acquisition plus the acquisition of a second company, bringing the number of companies in MedCana’s…

Continue Reading

ThursdayMar 28, 2024 3:29 pm

CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Focusing on ‘Overwhelming Interest’ for GLP-1 Applications of DehydraTECH(TM)

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that it will focus on glucagon-like peptide 1 (“GLP-1”) applications of its patented DehydraTECH(TM) technology for diabetes and weight loss for the 2024 calendar year. “This comes hot on the heels of a successful, active year of R&D in 2023, a year that saw significant strides in developing its patented DehydraTECH technology including its new foray into GLP-1 drugs… This laid the groundwork for Lexaria to explore a new class of molecules it had never worked on before, ultimately quietly launching its top-priority and unpublicized early-stage…

Continue Reading

ThursdayMar 14, 2024 3:45 pm

CBDNewsBreaks – Software Effective Solutions Corp. (SFWJ) Moving to Become World’s Premier Resource for High-Quality Pharmaceutical Products

Software Effective Solutions (OTC: SFWJ) (d/b/a MedCana) has established five companies focused on pharmaceutical cannabis production, managing processes for plant-to-patient operations, and irrigation and greenhouse technology. “A global infrastructure and holding company in the cannabis industry, MedCana is on a mission to become the world’s premier resource for pharmaceutical cannabis products,” reads a recent article that discusses the burgeoning global medical marijuana market and the increasing trend of cannabis decriminalization around the world. “With this backdrop of growing awareness and acceptance of medical cannabis, MedCana is well positioned to become an industry leader. The company has assembled a team of…

Continue Reading

TuesdayMar 05, 2024 2:05 pm

CBDNewsBreaks – Software Effective Solutions Corp. (SFWJ) Ideally Poised Amid Growing Evidence of Cannabis’ Benefits and Safety

Software Effective Solutions (OTC: SFWJ) (d/b/a MedCana), a global infrastructure and holding company in the cannabis industry, is paying close attention to growing data showing the power of cannabis. “One recent study, conducted by postdoctoral research fellow Thomas Arkell, a PhD at Swinburne University of Technology in Melbourne, Australia, suggests that medical cannabis treatment may be associated with improvements in health-related quality of life among patients with a range of health conditions. The results of the study were published earlier this year by JAMA Network Open… This is just one of innumerable studies focused on cannabis… ‘Based on evidence currently…

Continue Reading

MondayFeb 12, 2024 3:38 pm

CBDNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Patented DehydraTECH(TM) Improves Delivery of GLP-1 Drug to Bloodstream

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, announced the final results from its completed human Pilot Study #1 that sought to evaluate the effectiveness of its patented DehydraTECH(TM) technology on the oral delivery of the glucagon-like peptide-1 (“GLP-1”) drug semaglutide, available commercially in the branded product Rybelsus(R). “Most notable from its pilot study was the improved delivery of semaglutide to the bloodstream, which significantly improved blood sugar control. For one, in just 20 minutes after oral administration, the DehydraTECH-GLP-1 blood semaglutide level was about 261% higher than that of the control, a statistic that reflected…

Continue Reading

MondayFeb 12, 2024 3:01 pm

CBDNewsBreaks – Software Effective Solutions Corp. (SFWJ) Committed to Building Capabilities to Provide Pharmaceutical-Grade Cannabis Extracts to the World

Software Effective Solutions (OTC: SFWJ) is among companies in the cannabis space paying close attention to the mounting calls for the rescheduling of cannabis to a Schedule III from a Schedule I substance per the Controlled Substances Act (“CSA”). “The call for cannabis rescheduling on the CSA list is not new, but it has gained momentum since the U.S. Department of Health and Human Services (‘HHS’) sent a brief letter to the head of the U.S. Drug Enforcement Administration… ‘HHS is believed to have advised DEA to move marijuana from Schedule I to Schedule III of the Controlled Substances Act…

Continue Reading

FridayJan 12, 2024 3:30 pm

CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Grow Revenue and Commercial Opportunities Through Licensing

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, is committed to providing healthier delivery methods of drugs and other active pharmaceutical ingredients (“APIs”) through its patented drug delivery technology, DehydraTECH(TM). “The company’s efforts have focused on several key segments, including hypertension, diabetes, antivirals, epilepsy, nicotine replacement, and more. This has been an ongoing process since 2016, with positive results achieved from various clinical studies thus far, showing up to 17x brain absorption improvements for oral administration of APIs… Human clinical studies have been conducted since 2018, with more on the way,” a recent article reads. “With…

Continue Reading

TuesdayDec 26, 2023 3:44 pm

CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Leveraging Commercial Viability of DehydraTECH(TM) in Aggressive Patent Application Push

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, is eyeing growth in license revenue from its intellectual property (“IP”). “So far, Lexaria has received 37 granted patents globally, with many pending. The company is aggressively pushing its patent application process as it recognizes the viable commercial application of its flagship technology. In addition, the company understands that successfully granted patents can lead to an increase in shareholder value as a recognized growing market leader,” a recent article reads. “‘Because of the applicability of DehydraTECH to many market sectors across the globe, we have taken the necessary…

Continue Reading

FridayDec 15, 2023 3:45 pm

CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting New and More Lucrative Global Markets

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, is exploring the impact of its patented DehydraTECH(TM) technology on the oral performance of GLP-1 drugs for the treatment of diabetes and weight loss. “The move could help Lexaria carve out an important market share for an industry that is projected to bring in between $150 billion and $200 billion a year. Given the positive results the company has achieved so far in its diabetes and hypertension clinical studies, Lexaria is optimistic that its foray into GLP-1 drugs will yield positive results and open up its technology to…

Continue Reading